Madrigal Pharmaceuticals, Inc.
MDGL
Jodie situation report
Madrigal Pharmaceuticals, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- Increase in revenue driven by increased demand for Rezdiffra in the United States in 2026.
Invalidation: The isolated read changes if MDGL's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind MDGL
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
PFEPfizer, Inc.partnerMay 6, 2026 ▾
“Key Developments In January 2026, we announced the expansion of our pipeline with an exclusive global license with Pfizer Inc.”
HTGCHercules Capital, Inc.lenderMay 6, 2026 ▾
“Credit Facilities Hercules Loan Facility In May 2022 we entered into a $250.0 million senior secured loan facility with Hercules Capital, Inc.”
Depended on by
ARWRArrowhead Pharmaceuticals, Inc.partnerMay 7, 2026 ▾
“Announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference (RNAi) therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
MDGL is currently a Leader in the organic co-movement group MASH Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for MDGL; it is not active in the latest market snapshot.